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Abstract  
 
Background: Tianeptine is an atypical antidepressant marketed as Stablon since the late 
1980’s. While chemically very similar to tricyclic antidepressants, tianeptine was thought to 
have the apparently paradoxical mechanism of action of enhancing serotonin reuptake. 
However, recent data highlight a multimodal pharmacology for tianeptine including actions 
at glutamatergic synapses (inhibiting NMDA receptors and an indirect effect on AMPA 
receptors) coupled with agonist effects at mu opioid receptors (-receptors). Objective:  
We have reviewed clinical and preclinical data for tianeptine to provide a comprehensive 
study of its pharmacology. Results: Clinical trials show that tianeptine is at least as 
efficacious as first-line antidepressant treatments, with improved tolerability as it is 
significantly less prone to disrupting the patient's normal functionality. Tianeptine appears 
more efficacious in males than females, although these gender-specific differences may 
be accounted for by pharmacokinetics. Preclinical data suggest that the ability to stabilise 
glutamatergic neurotransmission may underlie tianeptine’s ability to improve cognitive 
function and anxiety-related symptoms. Alternatively, -receptor activation of the mTOR 
signalling pathway could lead tianeptine to be a fast-acting antidepressant. Agonist actions 
at -receptors could also explain the potential abuse liability and dependence issues seen 
with high dose tianeptine. Conclusion: Tianeptine itself is off patent, but it still holds much 
promise as an experimental tool yielding valuable insights into the molecular mechanisms 
underlying depression. 
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1. Introduction 
Major depressive disorder (MDD) is a highly pervasive disorder, characterised by 
persistent low mood, low self-esteem and anhedonia. In the UK, depression affects 4 
million adults, 8.4% of the total population and has been linked with poor health, significant 
comorbidity and mortality [1-3]. MDD, therefore, is characterised as a severely debilitating 
disease with a major impact not only on a person's quality of life but can also place a 
massive financial strain on a country’s healthcare system. 
 
The prevalence of the monoamine hypothesis as a causative factor of depression has 
driven the development of therapies that aim at restoring the neurochemical imbalance in 
noradrenaline, serotonin and dopamine. The principle classes of antidepressants utilised 
to restore this neurochemical alteration are the monoamine oxidase inhibitors (MAOIs), 
tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs) and 
serotonin noradrenaline reuptake inhibitors (SNRIs).All four classes of antidepressants 
have proven to be catalysts by dramatically improving the quality of life of depressed 
patients [4]. These agents, however, are associated with limitations in their onset of action, 
efficacy, tolerability and safety. These antidepressants have a delayed time of onset as 
they usually take four to six weeks to exhibit a therapeutic benefit [5]. Problems with the 
efficacy of antidepressant therapy include drug resistance where between one and two-
thirds of patients will not respond to the first antidepressant prescribed and 15 to 33 
percent will not respond to multiple interventions [6-7]. In terms of tolerability, 
antidepressants that interfere with the serotonin system can lead to emotional detachment 
[8] and interfere with normal sexual function [9] thus discouraging patients from complying 
with therapy. Finally, in terms of safety, even though antidepressants are generally 
regarded as safe, they have been associated with life-threatening side-effects including 
cardiovascular effects [10] and, controversially, an increased risk of suicide [11-12]. 
 
Tianeptine is an atypical antidepressant with a novel mechanism of action. Marketed since 
the late 1980’s as Stablon, tianeptine is available in Europe, Latin America, and Asia as a 
treatment for MDD although it is not available in the UK or North America [13]. Here we 
review the evidence demonstrating the clinical efficacy and potential advantages of 
tianeptine as an antidepressant, alongside recent advances in understanding its unique 
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multimodal psychopharmacology which could shed light on the molecular mechanisms 
underlying depression. 
 
 
 
2. Clinical Efficacy of Tianeptine 
 
We have attempted a comprehensive review of all the accessible clinical trial information 
on tianeptine and our findings are summarized in Table 1. The clinical efficacy of 
tianeptine has been assessed in a vast number of clinical trials, including two small term 
placebo controlled double blind studies; their purpose being the assessment of the efficacy 
of tianeptine in adult patients of both genders with unipolar or bipolar depression [14-15]. 
Treatment of both male and female patients (n=129) with tianeptine (37.5 mg/day) for 42 
days resulted in a reduction in the Montgomery-Asberg depression scale (MADRS) of 
62.3% as compared to placebo (48.5%) [14].The efficacy of tianeptine has also been 
shown in long-term studies to assess remission and relapse. In one study, 286 adult 
patients of both genders were treated with tianeptine for 6 weeks [16]. The patients that 
responded to tianeptine (n=185) were then randomly assigned to tianeptine (37.5 mg/day, 
n=111) or placebo (n=74) for up to 18 months and were assessed for their rate of relapse 
and reoccurrence by using the Hamilton depression rating scale and the CGI scale [16]. 
The results of the trial revealed that by the 18-month timepoint, in tianeptine treated 
patients, the rate of relapse and reoccurrence was lower (16%) compared to placebo 
(36%) [16]. 
 
Most of the clinical studies investigating the antidepressant efficacy of tianeptine have 
compared its efficacy in parallel with other classes of antidepressants. In double-blind 
studies of 4-24 weeks duration, tianeptine (37.5mg/day) showed similar efficacy as the 
TCAs amitriptyline (75 mg/day) [17-18] and imipramine (150 mg/d) [15], the atypical 
antidepressant mianserin (60mg/day) [19] but also the SSRIs fluoxetine (20mg/day) [20] 
and paroxetine (20mg/day) [21]. Additionally, in a meta-analysis comparison with SSRIs, 
tianeptine was shown to be just as efficacious during the same treatment period of 6 
weeks [22]. 
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Clinical evidence also supports an improvement in cognitive function following treatment 
with tianeptine. A 42-day study was performed as a double-blind, controlled trial and it 
utilised hospitalised adult patients that were classified using the DSM-IV criteria as having 
major depression or bipolar disorder [23]. For the purposes of the study, adult patients of 
both genders were treated in parallel either with tianeptine (37.5 mg/d) or paroxetine 
(20mg/d) and were assessed for improvement in cognitive function [23]. The investigators 
reported that both antidepressants significantly boosted cognitive function by improving 
alertness, selective attention and problem solving [23]. Interestingly, they also reported 
that patients treated with tianeptine showed greater improvement in cognitive function, an 
observation, however, that did not reach statistical significance [23]. In a separate study of 
MDD patients treated with either tianeptine (37.5 mg/d) or escitalopram (10 mg/d) for 12 
weeks, both drugs improved subjective cognitive impairment of memory and concentration 
[24] Furthermore, these authors showed that tianeptine led to more improvements in 
neurocognitive functions, especially in commission errors and verbal immediate memory, 
compared with escitalopram [24].  
 
In addition to its anti-depressive properties, tianeptine has been suggested to exhibit 
anxiolytic effects. In adult depressed patients that had concomitant anxiety [19], tianeptine 
(37.5 mg/day) was shown to result in an approximately 52% reduction in anxiety scores as 
assessed by the MADRS [19]. Several studies of between 4-24 weeks have demonstrated 
that the anxiolytic profile of tianeptine is similar to that of amitriptyline [17-18] mianserin 
(60mg/day) [19] , fluoxetine (20mg/day)  [25] and paroxetine (20mg/day) [21] and even the 
benzodiazepine alprazolam (1.5mg/day) [19]. Other studies suggest that tianeptine is 
superior to fluoxetine at relieving anxiety; patients on tianeptine required 50% less 
concomitant anxiolytic treatment than fluoxetine-treated patients [25]; this suggests that 
tianeptine is more effective at relieving anxiety associated with depressive illness than the 
SSRI fluoxetine and possible other antidepressants of the same class. The ability of 
tianeptine to effectively treat anxiety symptoms in MDD patients may be related to its 
ability to improve neurocognitive deficits [26]. 
 
There is also strong clinical evidence that tianeptine is beneficial for overcoming treatment-
resistant depression when combined with other antidepressants [27-28]. Specifically, in 
one study, this concept was tested in an open-label, prospective, multicentre 6-weeks 
study that included 150 adult patients of mixed genders [27]. Patients were diagnosed with 
MDD and did not respond or partially responded to SSRI monotherapy [27]. The result of 
6 
 
the study revealed that 65% of the enrolled patients responded to a combination treatment 
with low dose of tianeptine ( ≤ 37.5 mg/day)  and around 40% of patients went into 
remission as defined by both the MADRS and Hamilton Depression Rating Scale (HDRS) 
[27]. Furthermore, the investigators reported that a combination with high doses of 
tianeptine (≥ 37.5 mg/day) produced a fourfold increase in the probability of the patients 
going into remission, as defined by HDRS, at the study end point; when patients were 
assessed using the MADRS there was a twofold increase in the probability [27].  
 
Finally, an interesting observation concerning the clinical efficacy of tianeptine is its 
tendency to exhibit gender-specific differences. In the study by Nickel et al. [23] comparing 
paroxetine with tianeptine, the authors concluded that both antidepressants were effective 
at reducing depressive symptoms in both genders, however, males had a greater 
response on tianeptine while females on paroxetine. Additionally, the gender-specific 
differences of tianeptine have been reported in a small trial involving 38 depressed adult 
patients of both genders [29]. This study compared the efficacy of tianeptine (37.5mg) vs 
paroxetine (20mg) with regard to their effects on sleep regulation [29]. The results showed 
that tianeptine was more effective at improving sleep pattern in males compared to 
females. 
 
Overall, tianeptine has well established clinical efficacy as an antidepressant; better than 
placebo and at least equivalent to first-line treatments (Table 1). The improvement in 
depression scores in MDD patients is also associated with an improvement in anxiety 
symptoms and in cognitive abilities. In terms of time of onset or rate of relapse to 
depressive episodes, tianeptine’s abilities are not conclusively better than other 
antidepressants [13]. Tianeptine may have the advantage of being better tolerated than 
other antidepressants. 
 
 
2.1 Safety and Tolerability of Tianeptine 
A number of safety studies from various clinical trials have described tianeptine as a well-
tolerated drug. The side effect profile of tianeptine is mostly associated with 
gastrointestinal disturbances such as nausea, constipation and abdominal pain but also 
with unwanted CNS effects including headaches, dizziness, and change in dream patterns 
[30]. Interestingly in a double-blind trial, the tolerability of tianeptine was superior to that of 
paroxetine where the incidence of dropout, due to side effects, was significantly lower (19 
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vs 6) [21]. Comparison of tianeptine with TCAs and MAOIs has yielded the same 
superiority in tolerability; tianeptine lacks the serious adverse effects on the cardiovascular 
and cholinergic system associated with these classes of antidepressants, leading to much 
less impairment on sleep, arousal, cognition, weight gain or psychomotor functioning [31]. 
Additionally, unlike MAOI, tianeptine lacks the life-threatening drug interactions [31]. 
Tianeptine’s safety credentials are furthermore enhanced by the fact that it has a very low 
overdose risk, therefore, has been classed as a drug with a low abuse potential.  
Surprisingly in a single case study, a patient abused tianeptine by consuming 50 times the 
recommended dose on a daily basis and no severe toxicity was observed [32]. 
 
Undoubtedly, one of the major drawbacks of current antidepressant treatments is the 
discontinuation symptoms that occur after cessation of treatment. In most cases this 
discontinuation syndrome is short-term and has no major impact on a person's quality of 
life; however in other cases, it may last longer and symptoms may interfere with normal 
functioning [33]. Tianeptine is one of the few, if not the only, antidepressant that has not 
been associated with a discontinuation syndrome. In an open study evaluating the safety 
of tianeptine in 1,858 patients in general practice, stopping the antidepressant was not 
associated with withdrawal or discontinuation symptoms [34]. 
  
Individuals suffering from MDD are associated with a high prevalence of sexual 
dysfunction. A French study involving 4557 outpatients concluded that the prevalence of 
sexual dysfunction was 35% for spontaneously reported problems and 69% for problems 
identified by physician questioning [35]. Antidepressant therapy is clinically proven to 
aggravate such problems; results from the same study revealed that patients on 
antidepressants increased the frequency of sexual dysfunction compared to the untreated 
patients [35]. However, this exacerbation is less frequent with tianeptine. In comparison 
with TCAs and SSRIs, tianeptine exhibited a lower incidence of sexual dysfunction having 
a similar rate of untreated patients [35].  Not only is tianeptine associated with decreased 
frequency of sexual dysfunction but it is shown to be beneficial in men with depression 
with erectile dysfunction. In a randomised, double-blind, placebo-controlled, crossover trial 
involving 68 male patients, tianeptine significantly improved their erection when compared 
with males on placebo [36]. 
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3. Neurobiological Effects of Tianeptine 
3.1 Brain Structure and Neurotrophic Effects 
Neuroplasticity is the ability of the adult and differentiated brain to adapt functionally and 
structurally to internal and external stimuli [37]. There are three main brain regions which 
undergo neuroplastic adaptation and are assumed to be affected during MDD; these 
regions are the hippocampus, the amygdala and the prefrontal cortex [38] which are 
responsible for controlling emotion, perceptions and contribute to cognitive function. It is 
believed that during MDD these regions undergo alterations in volume, reduction in 
neuronal size and density, decreased adult neurogenesis and glial density [39-42]. 
Specifically, a study involving 16 patients with depression revealed that in all cases the 
volume of the left side of the hippocampus was 19% smaller when compared to 16 non-
depressed patients [41]. In the amygdala, it has been suggested that during reoccurring 
episodes of depression the core amygdala volume is reduced [40], however following a 
first episode of depression the total amygdala volume is increased [42]. Finally, the 
prefrontal cortex has been associated with decreased volume of the grey and white matter 
[41,43]. 
 
Treatment with tianeptine has proven to be successful at reversing the alterations on brain 
structure and plasticity induced by chronic depressed and stress states. Specifically, this 
has been shown in a study performed on tree shrews that had been subjected to 
psychosocial stress, receiving chronic administration with tianeptine (50mg/kg) over the 
span of 28 days [44]. Tianeptine administration potentiated proliferation of dentate gyrus 
precursor granule cells and restored hippocampal volume [44]. A different study showed 
that tianeptine not only normalised the rate of proliferation but was also able to decrease 
cellular apoptosis in the hippocampus [45]. Tianeptine has also been shown to be effective 
in reversing stress-induced atrophy; treatment of male Sprague-Dawley rats with 
tianeptine prevented and reversed dendritic atrophy of hippocampal CA3 pyramidal 
neurones [46]. These effects of tianeptine may be mediated by increases in neurotrophic 
factors. Chronic treatment with tianeptine increased levels of brain-derived neurotrophic 
factor in the hippocampus and prefrontal cortex of rats [47]. 
 
3.2 Synaptic Plasticity 
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Synaptic plasticity is the ability of neurones to undergo activity-dependent alterations in 
synaptic function in order to determine how the synapse will respond to afferent activity 
[48]. Altered synaptic function and plasticity have been implicated in the pathophysiology 
of depression with abnormal synaptic plasticity in the regions of the hippocampus, 
amygdala and prefrontal cortex [49]. More specifically the use of animal models has 
revealed that acute and chronic stress inhibits the ability of the hippocampus and the 
prefrontal cortex to undergo long-term potentiation (LTP) [50-51]. In the amygdala, the 
opposite scenario is observed where acute and chronic stress potentiates LTP instead of 
inhibiting [51].  
 
Preclinical data involving tianeptine have shown its beneficial effects in reversing 
alterations in plasticity. Tianeptine (10mg/kg) successfully enhanced synaptic function in 
the hippocampus [52-53] and prefrontal cortex [53] while maintaining normal synaptic 
function in the amygdala [54] of male Sprague-Dawley rats; the potentiation of LTP was 
reported to occur immediately after tianeptine administration. Interestingly tianeptine 
reversed the inhibitory effects of stress on LTP and mediated generation of a form of low 
threshold potentiation known as burst potentiation (PBP) [53-54]; priming of PBP was 
independent of stress experience. Tianeptine had no impact on amplification of LTP in the 
basolateral nucleus of the amygdala following a stressful stimulus [54]. 
 
3.3 Memory and Cognition  
A functional consequence of MDD and stress involves impairment of cognitive and 
memory function. Impairment in memory function is believed to occur due to damage to 
the hippocampus by stress and its related hormones [50, 55]; particularly damage in the 
region is associated with altered spatial memory.  Tianeptine has been shown to improve 
memory function in several experiments. For instance, in the radial-arm water maze, 
tianeptine (10mg/kg) prevented stress-induced impairment of rat spatial memory brought 
about by exposure to a predator [56]. Fascinatingly, evidence from the same experiment 
suggests that tianeptine improves memory without affecting the stress-induced rise in 
glucocorticoid suggesting that tianeptine does not interfere with activation of the 
hypothalamic-pituitary-adrenal axis following stress [56]. These effects of tianeptine are 
consistent with findings obtained from adrenalectomised rats [55]. 
 
Unlike the hippocampus which is responsible for spatial memory, the amygdala plays a 
crucial role in the acquisition and storage of emotional memories. During MDD the 
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amygdala is thought to be dysregulated, with fear-related learning being impaired [57-58]. 
Specifically, it is hypothesised that the amygdala exhibits potentiation of synaptic function 
and LTP during intense emotional experiences [59-60] resulting in amplification of fear-
related behaviour.  In animal models of emotional learning, tianeptine has been shown to 
be effective in preventing stress-induced enhancement of the amygdala. In more detail, 
administration of tianeptine (10mg/kg) reduced auditory fear conditioning in rats; the 
authors report that these effects of tianeptine are observed after long-term administration 
and not acutely [61]. 
 
4. Psychopharmacology of Tianeptine 
4.1 Actions at the Serotonin Reuptake Transporter 
One molecular target of tianeptine is the serotonin reuptake transporter (SERT) – a 
transporter which mediates reuptake of serotonin in neurones [62].  The majority of 
clinically available antidepressants are SERT inhibitors, they bind to an allosteric site on 
SERT decreasing its activity [62-63]. SSRIs have been proposed to inhibit SERT by 
interacting with the C-terminal part of SERT containing the transmembrane domains 10 
and 12; specifically they form dipole-dipole interactions or hydrogen bonds with the 
benzene ring of the Tyr95 and make the transporter adopt a conformation that decreases 
the affinity for serotonin or reduces its rate of transport [62-63]. 
 
Tianeptine is chemically somewhat similar to tricyclic antidepressants, comprising of a 
core 3-chlorobenzothiazepine nucleus, and thus it exerts similar molecular behaviour in 
that it binds at the same allosteric site of SERT [64]. However, a major difference between 
TCAs and tianeptine is the presence of the amino heptanoic acid on C3; the presence of 
which gives tianeptine SERT enhancing properties [64]. This side chain is thought to lock 
the transporter in a conformation which increases affinity and reuptake (Vmax) of serotonin 
[65]. Therefore, unlike SERT inhibiting antidepressants, tianeptine is defined as a positive 
allosteric modulator of SERT or a serotonin reuptake enhancer. Early binding studies 
indicated that tianeptine was selective for SERT as it did not bind to receptors for 
serotonin, dopamine, glutamate, GABA, acetylcholine, noradrenaline or histamine nor did 
it affect the transporters for noradrenaline or dopamine [66-67]. 
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Similarly to other classes of antidepressant, tianeptine was anticipated to interfere with 
neurotransmission of the serotonin system, due to its apparent mechanism of action. 
Initially, this notion was shown to be true by experiments that revealed that acute and 
sustained administration of tianeptine (10mg/kg) decreased the synaptic availability of 
serotonin in rat brains [66, 68]. Additionally, administration of tianeptine was shown to 
decrease both the number and mRNA levels of SERT sites in the dorsal raphe nucleus of 
rat brain [69]. However, the validity of these studies has been questioned due to the 
technical limitations that could not be avoided at the time [70]. More recent studies 
performed on the corticolimbic structures of rats suggest that acute/chronic treatment with 
10 mg/kg tianeptine has a negligible effect on synaptic serotonin levels [70]. 
Electrophysiological studies on rat dorsal raphe nuclei revealed that sustained 
administration of 20mg/kg/day tianeptine did not alter the firing rate of serotonin neurons. 
Moreover, prolonged treatment with tianeptine did not impact on the activity of 
postsynaptic serotonin 1A receptors or the activity of presynaptic serotonin autoreceptors 
[71]. Additionally, the antidepressant effects of tianeptine have been shown to be 
potentiated after enhanced serotonergic transmission via the use of fluoxetine [72]. 
Collectively the results have led to the notion that direct serotonin system modulation is 
unlikely to be the mechanism of antidepressant efficacy of tianeptine. However, these 
findings do not preclude the possibility that clinically tianeptine modulates serotonin 
function since the doses used in these preclinical studies may not translate directly to 
clinical dosing.   
 
4.2 Glutamatergic Mechanisms Underlying Cognitive and Synaptic Effects of 
Tianeptine 
Glutamate is the most abundant excitatory neurotransmitter in the central nervous system 
playing a crucial role in many aspects of brain function including neuronal regeneration, 
dendritic branching and learning and memory behaviours [73-74]. Disturbances in 
glutamate signalling have been linked with mood disorders [75-76]. For example, changes 
in glutamate levels have been observed in the cerebrospinal fluid, brain tissue and plasma 
of individuals with mood disorders and suicide victims [77-78]. 
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In vitro and in vivo studies have shown that tianeptine normalises disrupted glutamatergic 
neurotransmission in the hippocampus and the amygdala. In rodents, during MDD and 
stress conditions, there is an increase in extracellular glutamate levels in the amygdala 
[79] and the hippocampus [80]. In the hippocampus, glutamate overactivity is associated 
with a decrease in neuronal size, density and ultimately volume [81]. This process is 
thought to be mediated via the mechanism of excitotoxicity [82]. Conversely, glutamate is 
thought to enhance amygdala function by inducing dendritic hypertrophy in the basolateral 
nucleus [83].Treatment with tianeptine has been associated with downregulation of the 
glial glutamate transporter GLUT-1 mRNA in the hippocampus of chronic restrained mice 
which is the hallmark of decreased glutamate levels. Additionally, tianeptine (10mg/kg) has 
been shown to inhibit the stress-induced increase in NMDA channel currents [84]. Stress-
induced increases in extracellular glutamate in the amygdala were inhibited by tianeptine, 
but not by fluoxetine [79]. More recently, an in vivo microdialysis study in rats subjected to 
repeated stress showed that tianeptine inhibited downregulation of vGLUT2 expression in 
the amygdala, downregulation of which indicates impairment of amygdala glutamate 
neurochemistry [85]. In the same study daily treatment of tianeptine was shown to modify 
glutamatergic tone in non-stressed control rats by enhancing vesicular localisation of 
SNAP-25.  
 
While tianeptine appears to stabilise the glutamatergic signalling, it also has effects on the 
ionotropic glutamate receptors. While both NMDA and AMPA receptors are crucial for the 
normal functioning of neurones, overstimulation of NMDA receptors leads to excitotoxicity 
while AMPA receptors do not [86]. It has been shown that antagonists of the NMDA 
receptor complex and positive modulators of AMPA receptors exhibit antidepressant-like 
effects in animal models [87]. Tianeptine is thought to perturb NMDA receptor function 
while it potentiates the function of AMPA receptors. Chronic administration of tianeptine 
(10mg/Kg/day) is associated with changes in the amplitude ratio of NMDA receptors to 
AMPA/kainate receptor-mediated currents that are altered during stress in CA3 
hippocampal neurone [84]. The mechanism by which tianeptine produces this dual effect 
upon the glutamate system may result from an interaction with the glycine allosteric site on 
NMDA receptors. Glycine facilitates excitation at NMDA receptors to varying extents 
depending on the NMDA receptor subunit composition. In mice, an antagonist of the 
glycine site on the NMDA receptor enhanced the antidepressant-like effects of tianeptine 
in the forced swim test, while D-serine blocked tianeptine’s effects [88]. These authors also 
showed that the AMPA receptor blocker NBQX reduced tianeptine’s antidepressant-like 
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effects [88]. Assuming that tianeptine does indeed interfere with the function of NMDA 
receptors this would result in the prevention of overactivation of the receptors thus 
preventing excitotoxicity but could also potentiate AMPA mediated signalling by inhibiting 
GABAergic neurotransmission via the action of NMDA receptors present in GABAergic 
interneurons [89]. The AMPA-related function is also thought to be enhanced via an action 
upon mTOR signalling.  
 
The mammalian/mechanistic target of rapamycin (mTOR) is an atypical serine/threonine 
kinase implicated in various neuronal functions including inducing neurogenesis, axonal 
sprouting and dendritic spine growth [90]. Emerging research into the mechanisms of 
action of ketamine, a fast-acting glutamatergic antidepressant, have highlighted the 
potential role of mTOR signalling in depression and in antidepressant responses [91]. 
Activation of AMPA and NMDA receptors results in the activation of the mTOR signalling 
cascade which in turn initiates various neurophysiological processes [91]. In addition, the 
mTOR pathway positively regulates the glutamatergic system by increasing the expression 
and release of BDNF which acts upon theTrkB receptors which in turn increase the 
translation and trafficking of AMPA receptors on the cell membrane of neurons [91]. 
Preclinical studies utilising animal models of depression have reported decreased mTOR 
activation in the amygdala [92], PFC [93] and hippocampus [94]. Interestingly, in a recent 
paper it has been shown that in rat primary hippocampal neurones that have been 
exposed to toxic conditions, tianeptine reversed the structural abnormalities caused by 
stimulating dendritic outgrowth, spine density, and synaptic proteins and these effects 
were directly correlated with activation of the mTOR complex 1 (mTORC1) pathway [95]. 
 
The actions of tianeptine on mTOR signalling could explain tianeptine’s fast-acting 
antidepressant-like actions in animal models. Ketamine, for example, is a non-selective 
NMDA receptor antagonist which at low doses (10mg/kg) has been shown to have a 
potent antidepressant response in animal models of depression and this response is 
thought to be mediated by rapid activation of the mTOR signalling pathway [69]. 
Interestingly, ketamine has been shown to rapidly increase synapse spine formation, an 
effect which is mediated by increasing the levels of the postsynaptic proteins PSD95 and 
GluR1 and the presynaptic protein synapsin [97]. The process of synapse formation 
following ketamine administration was inhibited following ICV infusion of rapamycin, an 
mTOR-selective inhibitor, which also blocked the antidepressant effects of ketamine. 
Based on these findings ketamine is thought to produce its fast-acting responses by direct 
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activation of the mTOR signalling pathway (a process mediated via the enhancement of 
AMPA-mediated signalling) which results in spontaneous and sustained elevation of 
synapse-related proteins and therefore increase in synapse formation. Compared to 
ketamine, classic antidepressants which act upon monoamine signalling have also been 
shown to enhance mTOR signalling, however, they do not do this via a direct action upon 
the pathway and this is the reason why they are thought to take weeks to produce their 
antidepressant-response [98]. Thus tianeptine, which appears to also modulate mTOR 
signalling, as it enhances AMPA-related signalling, could elicit rapid antidepressant 
responses via this mechanism. 
 
 
4.3 Interactions with -receptors 
Clinically, recommended dosing with tianeptine is 37.5 mg/day. At high doses (75 up to 
3000 mg/day) tianeptine has been reported to be associated with a risk of abuse and 
dependency [99-106]. For example, Kisa et al [103] reported that a 34-year-old patient 
developed tianeptine dependence after using doses of 750 mg/day of tianeptine for one 
year. Evidence also suggests that tianeptine dependence is likely to develop in patients 
with substance dependence [99-101, 104]. Furthermore, it has been reported that a 
mother using 650 mg per day, and her newborn baby, were dependent on tianeptine [106]. 
The newborn baby suffered from neonatal abstinence syndrome after delivery and was 
successfully treated with morphine and urine drug screen was negative for both the mother 
and newborn [106]. 
This is perhaps not surprising in light of preclinical studies demonstrating that tianeptine 
can increase dopamine release; an effect associated with euphoria and the rewarding 
properties of drugs of abuse [108]. In rats, tianeptine at 5 mg/kg increased extracellular 
dopamine levels in the nucleus accumbens and at higher doses (10mg/kg) in the striatum 
and frontal cortex [109, 110]. These effects were independent of any serotonin mediated 
actions of tianeptine [109] and could account for the apparent abuse and dependency 
seen at higher doses of tianeptine.  
 
Ari et al [107] reported that naloxone (a non-selective opioid receptor antagonist) was 
effective in the treatment of amitriptyline and tianeptine poisoning in a 33-year-old woman 
with respiratory arrest and signs of opioid poisoning. These authors suggested that the 
high dose tianeptine and amitriptyline interacted with opioid receptors since naloxone 
effectively reversed these effects. Interestingly, analgesic effects of tianeptine have been 
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reported where 10 mg/kg produced a significant increase in reaction time on tail-flick 
latency or hot-plate in mice [111]. These authors suggested that tianeptine's effects were 
mediated via an interaction with serotonin since inhibiting biosynthesis blocked the 
analgesic actions of tianeptine. However, it has also been reported that the combination of 
morphine with tianeptine significantly decreased morphine antinociceptive tolerance and 
suppressed the incidence of naloxone-precipitated withdrawal symptoms in mice [112]. 
 
Tianeptine’s action at opioid receptors has recently been demonstrated using radioligand 
binding and functional cell-based assays [113]. Tianeptine has been shown to bind and act 
as a -receptor agonist (Ki (human) 383 ± 183 nM; EC50 (human) 194 ± 70 nM; EC50 
(mouse)  641 ± 120 nM), a lower efficacy delta-opioid receptor (-receptor) agonist (EC50 
(human) 37.4 ± 11.2 μM; EC50 (mouse) 14.5 ± 6.6 μM) and inactive at the kappa-opioid 
receptor (-receptor) [113]. These authors also demonstrated that tianeptine has no 
agonist or antagonist activity at metabotropic glutamate receptors. They further proposed 
that the activation of -receptor signalling by tianeptine could trigger dopamine release 
which may be responsible for the modulation of the glutamatergic system; dopamine 
acting at presynaptic dopamine receptors on glutamatergic presynaptic terminals could 
enhance glutamate signalling. Such a mechanism could account for the corrective effect of 
tianeptine on increased NMDA receptor signalling in stressed animals [115].   
 
Activation of -receptors could explain the potential abuse liability and dependence issues 
seen with high dose tianeptine. However, activation of both - and -receptors could also 
contribute to the antidepressant actions of tianeptine. Opiates have been used historically 
as antidepressants and opioid receptors are increasingly recognised to play a role in the 
regulation of mood and emotional behaviours [115-116]. For example, the partial -
receptor agonist buprenorphine, which also has -receptor antagonist properties, has 
antidepressant effects in patients and antidepressant-like activity in mice [117-119]. Indeed 
the acute and chronic antidepressant-like behavioral effects of tianeptine have recently 
been shown to require the -receptor using -receptor deficient mice [120]. Furthermore, 
the hypophagic, analgesic, hyperactive and conditioned place preference effects of 
tianeptine were all dependent on the -receptor [120]. Interestingly, one downstream effect 
of -receptor activation is regulation of mTOR signalling [121]. Tianeptine’s -receptor 
agonist properties [113] could lead to enhanced AMPA-related signalling since it promotes 
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mTOR activation which in turn increases the translation and trafficking of AMPA receptors 
in neurones.  
 
5. Pharmacokinetics of Tianeptine 
In healthy individuals, the pharmacokinetic properties of tianeptine have been extensively 
studied. Once in the gastrointestinal tract, tianeptine is rapidly absorbed and has a high 
bioavailability (90%) [122]. The absorption of tianeptine is modestly influenced by food 
intake, with both the time to reach maximum concentrations and lower peak 
concentrations increasing by 0.5h and 25% respectively [123]. Once in the blood stream, 
tianeptine becomes highly (95%) bound to the plasma protein human serum albumin; this 
aspect is associated with tianeptine’s poor volume of distribution [122]. In addition, 
tianeptine also exhibits saturable binding to the α1-acid glycoprotein [125]. Once in the 
blood stream, tianeptine is primarily metabolised by hepatic enzymes and undergoes -
oxidation of its heptanoic side-chain leading to the generation of two major metabolites; 
MC5 and MC3 [122]. Only MC5 is known to possess pharmacological activity [124]. 
Indeed, MC5 has been shown to elicit -receptor dependent antidepressant behavioural 
effects comparable to tianeptine [120]. 
 
Tianeptine shows rapid elimination from the body with a short terminal half-life of 2.5h; it is 
mainly excreted in the urine via the kidneys [122]. Taking into account the pivotal role of 
the kidneys in the clearance of tianeptine, individuals with impaired kidney function exhibit 
altered tianeptine pharmacokinetic properties. Clinical studies on volunteers with varying 
degrees of renal impairment report an elongation in the terminal half-life of tianeptine [124] 
.  Moreover, there seems to be a dramatic heightening of the terminal half-life of the 
metabolite MC5 in patients with renal failure [124].  
 
In healthy elderly populations, the pharmacokinetic characteristics of tianeptine are very 
similar to those of healthy younger adults. A moderate increase of 1.0h is observed in the 
terminal half-life of tianeptine [125]. However, a major difference between these 
populations lies in the levels of the metabolite MC5, with significantly higher levels being 
observed in the elderly [125]. Since MC5 has a longer half-life than tianeptine and exhibits 
pharmacological activity, the occurrence of adverse effects may be higher in elderly and 
reduced doses may be appropriate.  
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Tianeptine has been associated with gender-specific differences in efficacy which may be 
attributable to gender differences in pharmacokinetics. In females the volume of 
distribution is modestly lower when compared to that of males; specifically, the volume of 
distribution is 31% lower in women [126]. While most clinicians believe that this difference 
is of no clinical significance, it may indeed explain the reason as to why some clinical 
studies have reported tianeptine to be more efficacious in male populations. 
 
 
 
6. Conclusion  
Clinically tianeptine is as efficacious as SSRIs with more rapid improvements in cognitive 
function and anxiety relieving properties. What is more, in terms of safety and tolerability 
tianeptine is particularly attractive since clinical studies have shown it to be less hazardous 
and significantly less prone to disrupting the patient’s normal functionality. Tianeptine’s 
multimodal pharmacology, summarized in figure 1, may underlie this clinical profile. 
Tianeptine is an atypical antidepressant acting at SERT to stimulate serotonin reuptake, 
although this mechanism is unlikely to explain tianeptine’s antidepressant properties. One 
more plausible mechanism by which tianeptine produces its antidepressant and 
neurorestorative properties is via modulation of the glutamatergic system which is 
achieved by an effect upon the glycine site of the NMDA receptor; inhibiting its function, 
and mTOR signalling by indirectly enhancing AMPA-related signalling. Additionally, 
tianeptine’s antidepressant actions in mice have recently been shown to be dependent on 
the -receptor which in turn could activate mTOR signalling to enhance AMPA related 
signalling. Tianeptine itself is off patent, but it still holds much promise as an experimental 
tool, yielding valuable insights into the molecular mechanisms underlying depression. 
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Figure 1. Proposed pharmacological mechanisms of action of the multimodal 
antidepressant tianeptine. Tianeptine binds to the serotonin reuptake transporter (SERT) 
and may enhance synaptic levels of serotonin although this mechanism is unlikely to 
account for antidepressant effects. Tianeptine interacts with the glycine modulatory site of 
the glutamate ionotropic NMDA receptor which could alter mammalian/mechanistic target 
of rapamycin (mTOR) signalling and affect downstream mediators such as brain derived 
neurotrophic factor (BDNF) and the glutamate ionotropic AMPA receptor. Furthermore, 
tianeptine is an agonist at opioid receptors (OR) which could also activate mTOR 
signalling and stimulate dopamine release. 
 
 
 
 
Table 1.  Summary of clinical trials and case reports of patients with major 
depressive disorder (MDD) and bipolar disorder taking tianeptine. Reports are 
presented in chronological order and is an attempt to list all the available trials accessed 
via PubMed database search. The experimental study design, depression rating scales 
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used to determine outcomes, results and adverse effects/safety/tolerability are commented 
on.  
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REFERENCE PATIENT 
PROFILE 
EXPERIMENTAL 
DESIGN 
OUTCOME 
MEASURES 
RESULTS ADVERSE-EFFECTS 
Alby et al., 1993      206 patients, 
both genders, 
with MDD and 
dysthymia with 
associated 
somatic 
complaints 
90-day double-blind 
trial comparing the 
efficacy and 
acceptability of 
tianeptine (37.5 
mg/day) versus 
fluoxetine 
HARD and 
FARD scores 
Tianeptine and fluoxetine produced 
identical efficacy in terms of 
antidepressant and anxiolytic 
response as well as improvement in 
somatic complaints. Fluoxetine 
treated patients however required 
tranquilizers more often  added to 
their prescription in order to achieve 
similar antidepressant response as 
patients taking tianeptine 
 
Tianeptine was well tolerated by 
patients 
 
Invernizzi et al., 
1994 
300 MDD 
patients, both 
genders 
6 week double-
blind controlled 
study comparing 
tianeptine (37.5 
mg/day)  to 
amitriptyline 
 
HDRS, SAD, 
CGI Scores 
Tianeptine is an effective antidepressant and is associated with less 
somatic complaints and side effects when compared to amytriptiline 
Ansseau et al., 
1996 
 
152 patients 
with adjustment 
disorder with 
mixed emotional 
features (anxiety 
and 
depression), 
both genders 
 
6 week multicenter 
comparison study 
of tianeptine(37.5 
mg/day)  versus 
alprazolam and 
mianserin 
CGI,HARS, 
MADRS, 
VAS, AMPD 
Scores 
Tianeptine produces equipotent 
anxiolytic effects with alprazolam and 
mianserin 
Tianeptine was associated with 
clinically insignificant side-
effects 
Cassano et al., 
1996 
 
187 MDD and 
Bipolar Disorder 
patients, both 
genders 
6 Week Double-
blind parallel group 
study of tianeptine 
(25-50 mg/day; 
mean dose 37.5 
mg/day) versus 
placebo and 
imipramine. 
MADRS 
Scores 
Tianeptine is effective in the 
treatment of MDD and depression 
associated with bipolar disorder. No 
difference in efficacy was found 
between tianeptine and imipramine 
No difference in adverse effects 
was found between tianeptine 
and placebo. Assessment of 
hematological ,renal, metabolic 
and hepatic parameters 
confirmed safety of tianeptine; it 
produces no side-effects 
associated with the tricyclic 
antidepressant imipramine 
 
Costa e Silva et 126 MDD and 42 days long MADRS, Tianeptine is effective in the Tianeptine's acceptability did not 
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al., 1997  Bipolar Disorder 
patients, 
Depressed with 
or without 
melancholia, 
both genders 
multicentre 
randomised, 
double-blind, 
parallel group study 
of tianeptine (25-50 
mg/day; mean dose 
37.5 mg/day)  
versus placebo 
 
CGI, HARS, 
Zung DSR 
and VAS 
scores 
treatment for patients with MDD or 
Bipolar Disorder associated 
Depression, with or without 
melancholic features 
differ from that of placebo. For 
adverse events, a higher 
incidence of headaches was 
found with tianeptine. 
Vandel et al., 
1999  
30 year old 
female MDD 
patient 
Case study 
reporting the abuse 
potential of 
tianeptine (37.5 
mg/day) 
Abuse 
potential was 
assessed 
based on 
whether the 
patients 
altered the 
dosage 
regime on 
their own 
Tianeptine was associated with 
abuse potential with the patient 
spontaneously increasing the dosage 
which after two months reached 150 
tablets per day.  
 
The discontinuation of the tianeptine 
treatment occurred four days after 
hospitalization. 
150mg/day of tianeptine was not 
associated with any severe toxic 
effects. In the beginning of this 
high treatment period reported 
nausea, vomiting, abdominal 
pain, anorexia with weight loss, 
constipation; these side effects 
progressively disappeared. 
Delery et al., 
2001 
 
268 recurrent 
MDD patients, 
both genders 
6-week multicentre 
open cooperative 
study of tianeptine 
(37.5 mg/day) 
versus placebo 
Kaplan-Meier 
survival 
curve 
analysis 
Tianeptine decreases relapse and 
recurrence of MDD by two to 
threefold compared to placebo and 
was supported for use in the long-
term treatment of MDD 
No difference in adverse effects 
was found between tianeptine 
and placebo. 
Guelfi et al., 
2001  
1858 MDD 
without 
melancholia or 
psychotic 
features 
patients, both 
genders 
3-month long open 
study in general 
practice assessing 
tianeptine (37.5 
mg/day) 
acceptability 
MADRS 
Scores 
Tianeptine was not associated with cardiovascular,  hematologic, 
hepatic and biochemical abnormalities while it was not associated with 
dependence nor with withdrawal symptoms following discontinuation of 
treatment 
Lepine et al., 
2001  
366 MDD 
patients without 
past or current 
history of co-
morbid anxiety 
and/or important 
anxiolytic 
treatment, both 
genders 
6-week, double 
blind comparison 
trial of tianeptine 
(37.5 mg/day) with 
paroxetine 
effectiveness with 
special focus on 
improvement 
anxious symptoms 
MADRS and 
HDRS 
Scores 
Tianeptine and paroxetine exhibited 
equipotent efficacy on depressive  
symptomatology and act directly on 
the anxious components of 
depression 
 
Tolerability of both drugs was 
good, although significantly 
better with tianeptine  
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Kasper and 
Olie, 2002  
1378 MDD 
patients, both 
genders 
Meta-analysis 
comparing the 
efficacy of 
tianeptine (37.5 
mg/day) versus 
fluoxetine in the 
short treatment of 
depression 
MADRS AND 
CGI Scores 
Both tianeptine and fluoxetine 
produced significant antidepressant 
response with greater efficacy in 
favor of  tianeptine 
Tianeptine has a better 
acceptability profile than the 
SSRI fluoxetine 
Novotny and 
Faltus, 2002   
178 MDD 
patients, both 
genders 
6-week, 
multicentre, 
randomised, 
double-blind 
controlled study 
comparing 
tianeptine (37.5 
mg/day) to 
fluoxetine 
MADRS, 
CGI, COVI 
Scores 
Tianeptine was as efficacious as fluoxetine in its antidepressant 
response and was well tolerated by patients 
Bonierbale et 
al., 2003  
237 male 
patients with 
mild to 
moderate 
depression with 
erectile 
dysfunction 
8-weeks 
randomized, 
double-blind, 
placebo-controlled, 
crossover trial of 
tianeptine (37.5 
mg/day) 
ADS, Brief 
Sexual 
Inventory, 
and Quality-
of-life and 
erection 
questionnaire 
scores 
Tianeptine significantly improved the males erection when controlled 
with males on placebo 
Guillem and 
Lepin, 2003  
42 year old male 
MDD patient 
Case study 
reporting the abuse 
potential of 
tianeptine (37.5 
mg/day) 
 The patient alleged a "flash sensation" like with heroin with the very first 
doses, psychological well-being sensation, better psychomotor 
performances and transient mood elation. His addiction to tianeptine 
was immediate and heavy, reaching 240 tablets/day. The positive 
reinforcement faded away after one month and a total dependence took 
over, with physical and psychological withdrawal symptoms when doses 
were not renewed. 
Letere et al., 
2003  
5 MDD patients, 
both genders 
Case study 
reporting five cases 
of excessive 
consumption of 
tianeptine (37.5 
mg/day) 
DSM IV, CIM 
10 criteria  
The five patients exhibited 
pathological profiles of psychoactive 
drug abusers in that tianeptine was 
always used in higher than 
recommended dosages and was 
taken in association with other 
psychotropes. 
 
Withdrawal due to tianeptine 
misuse was difficult and induced 
anxiety and other disorders and 
led to relapse in most of the 
patients 
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Nickel et al., 
2003  
42 MDD and 
Bipolar Disorder 
patients, both 
genders 
42 days double-
blind randomized 
controlled studies 
comparing the 
clinical and 
neurobiological 
effects of tianeptine 
(37.5 mg/day) 
versus paroxetine 
HAMD, 
MADRS, 
CGI, BDI 
Tianeptine and paroxetine improved 
depressive symptomatology, restored 
neurobiology and enhanced cognition 
equipotently. Paroxetine, however 
was associated with a better 
response amongst women 
Tianeptine was well tolerated by 
patients 
Niederhofer, 
2003  
32 year old 
female patient 
with treatment 
resistant MDD 
Case study 
reporting the 
effectiveness of 
tianeptine 
(≤37.5mg/day) as a 
add-on therapy in 
treatment resistant 
depression 
 
HAM-D Combination of antidepressants and 
Tianeptine significantly reduced 
depression symptomatology in 
treatment resistant depression 
Combination of tianeptine with 
other classes of antidepressants 
was well tolerated 
Murck et al., 
2003 
38 MDD 
patients, both 
genders 
42-day comparative 
trial assessing  the 
effects of tianeptine 
(37.5mg/day) 
versus paroxetine 
on sleep regulation 
Spectral 
analysis of 
the non-REM 
sleep EEG 
Spectral analysis of the non-REM 
sleep EEG revealed a strong decline 
in the higher sigma frequency range 
(14-16 Hz) in male treatment 
responders independent of 
medication. The patients receiving 
paroxetine showed less REM sleep 
and more intermittent wakefulness 
compared to the patients 
receiving tianeptine 
 
Tianpetine was well tolerated by 
patients 
Saatcioglu et al., 
2006  
24 year old 
MDD patient 
Case study 
reporting the abuse 
potential of 
tianeptine 
(37.5mg/day) 
Abuse 
potential of 
tianpetine 
assessed 
based on  
symptoms 
and  
spontaneous 
increases in 
dosage 
regimes 
Tianeptine was associated a strong 
feeling of wellbeing when taken and 
led to physical withdrawal symptoms 
following abrupt discontinuation. 
Moreover it led to tolerance and the 
patient had to increase the dosage to 
experience tianeptine’s positive 
reinforcing properties; specifically the 
patient was reported to reach doses 
as high as 3000mg/day. 
3000mg/day of tianeptine was 
excellently tolerated by the 
patient and did not alter hepatic 
parameters. 
Kisa et al., 2007  34 year old Case study Abuse Tianpetine was associated with psychostimuant effects that led to 
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female MDD 
patient 
reporting the abuse 
potential of 
tianeptine 
(37.5mg/day) 
potential of 
tianpetine 
was 
assessed 
based on  
symptomatol
ogy and  
spontaneous 
increases in 
dosage 
regimes 
misuse (with the patient reaching doses of 750mg/day) and 
dependence. Moreover tianeptine led to symptoms of deprivation in the 
absence of the drug. 
Ari et al., 2010  33 year old 
female MDD 
patient 
Case study 
assessing the 
potential use of 
naloxone in 
tianeptine overdose 
 
Improvement 
in the 
Glasgow 
coma score 
Naloxone combination with supportive care is an effective treatment 
regime for the management of tianeptine poisoning. Exact dosages that 
lead to tianeptine toxicity were not reported 
Woo et al., 2013  150 MDD 
patients that had 
not responded 
to previous 
SSRI 
monotherapy,  
both genders 
 
6-week open-label 
study comparing 
the efficacy of 
tianeptine 
(≤37.5mg/day) as 
an add-on therapy 
HDRS,MAD
RS and CGI 
Scores 
A combination strategy 
with tianeptine may be an effective 
and well-tolerated tool for patients 
who have failed to adequately 
respond to SSRI monotherapy. 
Tianeptine and SSRI 
combination was generally well-
tolerated. 
Jeon et al., 2014  
 
164 MDD 
patients, both 
genders 
12-week, 
multicentre, 
randomized 
comparative trial 
of tianeptine 
(37.5mg/day) versu
s escitalopram on 
improvement of 
neurocognitive  
function 
 
Mini-Mental 
State 
Examination, 
the 
Continuous 
Performance 
Test(MMSE), 
the Verbal 
Learning 
Test(VLT), 
and the 
Raven 
Progressive 
Matrices(RP
M) 
Both drugs improved subjective 
cognitive impairment of memory and 
concentration. Tianeptine, 
however, led to more profound 
improvements in neurocognitive 
functions, especially in commission 
errors and verbal immediate memory, 
compared with escitalopram, 
 
Tianeptine was well tolerated by 
patients 
Yoo et al., 2015 164 MDD 12-week, HAM-A, Improvement in anxiety symptoms Tianeptine was well tolerated by 
37 
 
 patients, both 
genders 
multicentre, 
randomized 
trial comparing 
tianeptine  
(37.5mg/day) to 
escitalopram 
HAM-D, 
MMSE,CPT,
VLT,RPM 
due to  tianeptine and escitalopram 
use were significantly associated with 
improvement in subjective and 
objective neurocognitive functions 
such as delayed memory and 
reasoning ability in elderly MDD 
patients; However it was not 
associated with improvements on 
immediate memory and commission 
error 
 
patients 
Bence et al., 
2016 
Pregnant female 
MDD patient 
Case study 
reporting the impact 
of tianeptine 
(37.5mg/day) 
abuse on the 
mother-child dyad 
Abuse 
potential  
assessed 
based on 
symptom and 
spontaneous 
increases in 
tianeptine 
doses 
The female patient presented with dependence on tianeptine, with the 
use of >650 mg of the drug per day. The state of dependence remained 
unidentified throughout the first pregnancy, but just after delivery, her 
full-term newborn exhibited unexpected neonatal abstinence syndrome 
(NAS) which was successfully treated with morphine. 
 
 
 
